1. Home
  2. FSLY vs RCUS Comparison

FSLY vs RCUS Comparison

Compare FSLY & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fastly Inc.

FSLY

Fastly Inc.

HOLD

Current Price

$33.99

Market Cap

3.5B

Sector

Technology

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$22.88

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSLY
RCUS
Founded
2011
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
2.8B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
FSLY
RCUS
Price
$33.99
$22.88
Analyst Decision
Hold
Buy
Analyst Count
7
11
Target Price
$15.67
$30.27
AVG Volume (30 Days)
10.6M
942.6K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
27.19
N/A
EPS
N/A
N/A
Revenue
$624,018,000.00
$247,000,000.00
Revenue This Year
$16.43
N/A
Revenue Next Year
$10.45
$70.88
P/E Ratio
N/A
N/A
Revenue Growth
14.78
N/A
52 Week Low
$5.13
$7.06
52 Week High
$34.22
$26.40

Technical Indicators

Market Signals
Indicator
FSLY
RCUS
Relative Strength Index (RSI) 69.83 55.73
Support Level $8.03 $20.18
Resistance Level N/A $24.62
Average True Range (ATR) 2.69 1.09
MACD 0.20 0.11
Stochastic Oscillator 92.95 83.62

Price Performance

Historical Comparison
FSLY
RCUS

About FSLY Fastly Inc.

Fastly Inc is a cloud computing company that provides an edge cloud platform designed to deliver, secure, and optimize digital experiences over the internet. The company operates a unified platform that combines content delivery, edge computing, and security capabilities. Its services include content delivery networks, web and API protection, distributed denial of service mitigation, and real-time data processing at the edge. Its platform enables customers to improve the performance, scalability, and security of applications and digital content, and also supports cloud-native architectures, AI-driven workloads, and programmable edge computing solutions.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: